A Window of Opportunity Trial of NT-I7 in Patients With Locally Recurrent Squamous Cell Carcinoma of Head and Neck (SCCHN) Undergoing Salvage Surgery
Latest Information Update: 10 Jun 2024
At a glance
- Drugs Efineptakin alfa (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- 05 Jun 2024 Planned End Date changed from 31 Mar 2024 to 31 Mar 2025.
- 05 Jun 2024 Planned primary completion date changed from 31 Mar 2024 to 31 Mar 2025.
- 12 Apr 2023 Planned End Date changed from 31 Mar 2023 to 31 Mar 2024.